Back to Cell Types

KLEHomo sapiens (Human)Cancer cell line

🤖 AI SummaryBased on 13 publications

Quick Overview

Human endometrial cancer cell line with unique characteristics for research.

Detailed Summary

The KLE cell line is derived from a poorly differentiated endometrial carcinoma and exhibits aneuploid characteristics with chromosome numbers ranging from 51 to 66. It is notable for its defective estrogen receptor translocation, making it a unique model for studying endometrial cancer. The cell line has been used in various studies to evaluate chemosensitivity, radiosensitivity, and the mechanisms of tumor progression. KLE cells show variability in their response to platinum-based therapies and have been utilized in in vitro and in vivo experiments to understand cancer biology and therapeutic strategies.

Research Applications

Chemosensitivity testingRadiosensitivity analysisEstrogen receptor studiesTumor progression mechanismsIn vitro and in vivo drug testing

Key Characteristics

Aneuploid karyotypeDefective estrogen receptor translocationVariable response to platinum-based therapiesUsed in in vitro and in vivo studies

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1329
Species	Homo sapiens (Human)
Tissue Source	Endometrium[UBERON:UBERON_0001295]

Donor Information

Age	68
Age Category	Adult
Sex	Female
Race	caucasian

Disease Information

Disease	Type II endometrial adenocarcinoma
Lineage	Uterus
Subtype	Endometrial Carcinoma
OncoTree Code	UCEC

DepMap Information

Source Type	ATCC
Source ID	ACH-000293_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg175His (c.524G>A)	Unspecified	Somatic mutation acquired during proliferation	from parent cell line YCC-3
MutationSimple	FBXW7	p.Arg479Gln (c.1436G>A)	Heterozygous	-	Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

13,14

D13S317

12

D16S539

11,12

D18S51

13,17

D19S433

15

D21S11

28,30

D2S1338

18,19

D3S1358

17

D5S818

9,12

D7S820

11,12

D8S1179

8,14

FGA

23,25

Penta D

13

Penta E

7

TH01

6,7

TPOX

8,11

vWA

16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Genomic characterization of five commonly used endometrial cancer cell lines.

Devor E.J., Gonzalez-Bosquet J., Thiel K.W., Leslie K.K.

Int. J. Oncol. 57:1348-1357(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Lessey B.A., Jordan V.C., Bradford A.P.

Gynecol. Oncol. 127:241-248(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Three-dimensional coculture of endometrial cancer cells and fibroblasts in human placenta derived collagen sponges and expression matrix metalloproteinases in these cells.

Tanaka R., Saito T., Ashihara K., Nishimura M., Mizumoto H., Kudo R.

Gynecol. Oncol. 90:297-304(2003).

p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines.

Syrjanen S.M.

Gynecol. Oncol. 71:352-358(1998).

Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.

Rantanen V., Grenman S.E., Kulmala J., Grenman R.

Br. J. Cancer 69:482-486(1994).

Sublethal damage repair after fractionated irradiation in endometrial cancer cell lines tested with the 96-well plate clonogenic assay.

Grenman R.

J. Cancer Res. Clin. Oncol. 120:712-716(1994).

KLE: a cell line with defective estrogen receptor derived from undifferentiated endometrial cancer.

Merk L.P., Bradley F.M.

Gynecol. Oncol. 17:213-230(1984).

Characteristics of cell lines derived from normal and malignant endometrial tissue.

Noumoff J.S., Haydock S.W., Sachdeva R., Heyner S., Pritchard M.L.

Gynecol. Oncol. 27:141-149(1987).

Radiation sensitivity of endometrial carcinoma in vitro.";

Rantanen V., Grenman S.E., Kulmala J., Salmi T., Grenman R.

Gynecol. Oncol. 44:217-222(1992).

Web Resources